Attention biotech history: Ginkgo pours $700M+ on just 2 execs
Ginkgo CEO Jason Kelly and COO Reshma Shetty just became two of the most highly paid executives in biotech history — sort of.
The controversial synthetic biology company, subject to nearly a year of scrutiny from journalists and short-sellers after a SPAC that valued it at $15 billion, released an annual report Wednesday that included the annual compensation for the two founder-executives: $364 million, apiece.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 163,500+ biopharma pros reading Endpoints daily — and it's free.